A5073767932- Pregnancy and Medication Impact
- Inflammatory Bowel Disease
- Microscopic Colitis
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Spondyloarthritis Studies and Treatments
AbbVie (Germany)
2022-2024
Data from phase IIb/III and III studies were used to characterize the population pharmacokinetics of risankizumab its exposure-response relationships for efficacy safety in ulcerative colitis (UC) patients. A two-compartment model with first-order absorption elimination accurately described pharmacokinetics. Although certain covariates, namely, body weight, serum albumin, fecal calprotectin, sex, corticosteroid use, advanced therapy inadequate response, pancolitis, statistically correlated...
The population pharmacokinetics (PK) of risankizumab and exposure-response relationships for efficacy safety in patients with Crohn's disease (CD) were characterized using data from phase II III studies to support dosing regimen selection. A two-compartment model first-order absorption elimination adequately described PK. Covariates including sex, baseline fecal calprotectin, corticosteroid use, creatinine clearance, body weight, albumin statistically correlated but their impact on exposure...
Risankizumab is an anti-IL23 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis (PsA). This work characterizes pharmacokinetics risankizumab in PsA compared with evaluates efficacy safety exposure-response relationships PsA. The population pharmacokinetic analyses included data from 1527 participants that originated one phase 1 healthy participant study, 2 dose-ranging study patients open-label extension two pivotal 3 studies...